Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission

Yoshinao Muro, Kazumitsu Sugiura, Kei Hoshino, Masashi Akiyama

研究成果: Article

60 引用 (Scopus)

抄録

Objective. Autoantibodies against melanoma differentiation-associated gene 5 (MDA-5) are one of the serological markers for DM. Anti-MDA-5 antibodies are especially associated with rapidly progressive interstitial lung disease (ILD) in amyopathic DM (ADM). It is known that the antibody status of anti-ENAs does not generally change significantly with disease course. For anti-MDA-5 antibodies, however, few longitudinal studies have investigated such changes. This study aimed to establish a quantitative assay for anti-MDA-5 antibodies towards assessing the long-term outcome of ADM patients who had anti-MDA-5 antibodies.Methods. We established ELISA for measuring anti-MDA-5 antibody levels using in vitro transcription and translation recombinant protein. The antibody levels were measured at different time points in 11 clinically ADM patients who tested positive for the anti-MDA-5 antibody on their first visit (range of follow-up 3 months to 16 years).Results. At the stage of clinical remission, six patients received no medication and the four others received low-dose CS. ELISA showed that anti-MDA-5 antibodies disappeared in nine of the patients and fell to just above the cut-off in one patient; in the patient who died, the antibodies remained.Conclusion. Our results suggest that anti-MDA-5 antibodies may be useful as a marker for monitoring disease activity in ILD complicated with ADM. Serial monitoring at short intervals is required to evaluate whether anti-MDA-5 antibody levels correlate with ADM disease activity.

元の言語English
記事番号ker408
ページ(範囲)800-804
ページ数5
ジャーナルRheumatology
51
発行部数5
DOI
出版物ステータスPublished - 01-05-2012

Fingerprint

Interstitial Lung Diseases
Autoantibodies
Melanoma
Antibodies
Genes
Enzyme-Linked Immunosorbent Assay
Recombinant Proteins
Longitudinal Studies

All Science Journal Classification (ASJC) codes

  • Rheumatology
  • Pharmacology (medical)

これを引用

@article{6abdb2c3e9b04a11bc16281773f8ab92,
title = "Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission",
abstract = "Objective. Autoantibodies against melanoma differentiation-associated gene 5 (MDA-5) are one of the serological markers for DM. Anti-MDA-5 antibodies are especially associated with rapidly progressive interstitial lung disease (ILD) in amyopathic DM (ADM). It is known that the antibody status of anti-ENAs does not generally change significantly with disease course. For anti-MDA-5 antibodies, however, few longitudinal studies have investigated such changes. This study aimed to establish a quantitative assay for anti-MDA-5 antibodies towards assessing the long-term outcome of ADM patients who had anti-MDA-5 antibodies.Methods. We established ELISA for measuring anti-MDA-5 antibody levels using in vitro transcription and translation recombinant protein. The antibody levels were measured at different time points in 11 clinically ADM patients who tested positive for the anti-MDA-5 antibody on their first visit (range of follow-up 3 months to 16 years).Results. At the stage of clinical remission, six patients received no medication and the four others received low-dose CS. ELISA showed that anti-MDA-5 antibodies disappeared in nine of the patients and fell to just above the cut-off in one patient; in the patient who died, the antibodies remained.Conclusion. Our results suggest that anti-MDA-5 antibodies may be useful as a marker for monitoring disease activity in ILD complicated with ADM. Serial monitoring at short intervals is required to evaluate whether anti-MDA-5 antibody levels correlate with ADM disease activity.",
author = "Yoshinao Muro and Kazumitsu Sugiura and Kei Hoshino and Masashi Akiyama",
year = "2012",
month = "5",
day = "1",
doi = "10.1093/rheumatology/ker408",
language = "English",
volume = "51",
pages = "800--804",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "5",

}

Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. / Muro, Yoshinao; Sugiura, Kazumitsu; Hoshino, Kei; Akiyama, Masashi.

:: Rheumatology, 巻 51, 番号 5, ker408, 01.05.2012, p. 800-804.

研究成果: Article

TY - JOUR

T1 - Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission

AU - Muro, Yoshinao

AU - Sugiura, Kazumitsu

AU - Hoshino, Kei

AU - Akiyama, Masashi

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Objective. Autoantibodies against melanoma differentiation-associated gene 5 (MDA-5) are one of the serological markers for DM. Anti-MDA-5 antibodies are especially associated with rapidly progressive interstitial lung disease (ILD) in amyopathic DM (ADM). It is known that the antibody status of anti-ENAs does not generally change significantly with disease course. For anti-MDA-5 antibodies, however, few longitudinal studies have investigated such changes. This study aimed to establish a quantitative assay for anti-MDA-5 antibodies towards assessing the long-term outcome of ADM patients who had anti-MDA-5 antibodies.Methods. We established ELISA for measuring anti-MDA-5 antibody levels using in vitro transcription and translation recombinant protein. The antibody levels were measured at different time points in 11 clinically ADM patients who tested positive for the anti-MDA-5 antibody on their first visit (range of follow-up 3 months to 16 years).Results. At the stage of clinical remission, six patients received no medication and the four others received low-dose CS. ELISA showed that anti-MDA-5 antibodies disappeared in nine of the patients and fell to just above the cut-off in one patient; in the patient who died, the antibodies remained.Conclusion. Our results suggest that anti-MDA-5 antibodies may be useful as a marker for monitoring disease activity in ILD complicated with ADM. Serial monitoring at short intervals is required to evaluate whether anti-MDA-5 antibody levels correlate with ADM disease activity.

AB - Objective. Autoantibodies against melanoma differentiation-associated gene 5 (MDA-5) are one of the serological markers for DM. Anti-MDA-5 antibodies are especially associated with rapidly progressive interstitial lung disease (ILD) in amyopathic DM (ADM). It is known that the antibody status of anti-ENAs does not generally change significantly with disease course. For anti-MDA-5 antibodies, however, few longitudinal studies have investigated such changes. This study aimed to establish a quantitative assay for anti-MDA-5 antibodies towards assessing the long-term outcome of ADM patients who had anti-MDA-5 antibodies.Methods. We established ELISA for measuring anti-MDA-5 antibody levels using in vitro transcription and translation recombinant protein. The antibody levels were measured at different time points in 11 clinically ADM patients who tested positive for the anti-MDA-5 antibody on their first visit (range of follow-up 3 months to 16 years).Results. At the stage of clinical remission, six patients received no medication and the four others received low-dose CS. ELISA showed that anti-MDA-5 antibodies disappeared in nine of the patients and fell to just above the cut-off in one patient; in the patient who died, the antibodies remained.Conclusion. Our results suggest that anti-MDA-5 antibodies may be useful as a marker for monitoring disease activity in ILD complicated with ADM. Serial monitoring at short intervals is required to evaluate whether anti-MDA-5 antibody levels correlate with ADM disease activity.

UR - http://www.scopus.com/inward/record.url?scp=84860235241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860235241&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/ker408

DO - 10.1093/rheumatology/ker408

M3 - Article

VL - 51

SP - 800

EP - 804

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 5

M1 - ker408

ER -